Perjeta Approved for Advanced Breast Cancer

<p><a href="http://www.womenshealth.gov">Home</a> </p>
<p> <a href="http://www.womenshealth.gov/news/">News</a><a href="http://www.womenshealth.gov/news/headlines">Health headlines</a> </p>
<p> <span>Perjeta Approved for Advanced Breast Cancer</span></p>
<p> <img alt="divider line" height="9" src="http://medicalinfo.info/wp-content/plugins/RSSPoster_PRO/cache/a2211_lr-fade.gif" width="760" /></p>
<p>MONDAY, Jun 11 (HealthDay News) — Perjeta (pertuzumab) has been authorized by a U.S. Food and Drug Administration to provide people with HER2-positive late-stage breast cancer, a group pronounced in a news release.</p>
<p>HER2 is a protein concerned in dungeon growth. Increased amounts of a protein, that tend to fuel cancer dungeon expansion and survival, are found in about 20 percent of breast cancer cases, a FDA said.</p>
<p>Perjeta was authorized for people ...